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Background: Following the success of Cognitive Behavioral Therapy (CBT) for insomnia,
there has been a growing recognition that similar treatment approaches might be
equally beneficial for other major sleep disorders, including non-rapid eye movement
(NREM) parasomnias. We have developed a novel, group-based, CBT-program for
NREM parasomnias (CBT-NREMP), with the primary aim of reducing NREM parasomnia
severity with relatively few treatment sessions.
Methods: We investigated the effectiveness of CBT-NREMP in 46
retrospectively-identified patients, who completed five outpatient therapy sessions.
The outcomes pre- and post- CBT-NREMP treatment on clinical measures of insomnia
(Insomnia Severity Index), NREM parasomnias (Paris Arousal Disorders Severity Scale)
and anxiety and depression (Hospital Anxiety and Depression Scale), were retrospectively
collected and analyzed. In order to investigate the temporal stability of CBT-NREMP, we
also assessed a subgroup of 8 patients during the 3 to 6 months follow-up period.
Results: CBT-NREMP led to a reduction in clinical measures of NREM parasomnia,
insomnia, and anxiety and depression severities [pre- vs. post-CBT-NREMP scores:
P (Insomnia Severity Index) = 0.000054; P (Paris Arousal Disorders Severity
Scale) = 0.00032; P (Hospital Anxiety and Depression Scale)= 0.037]. Improvements in
clinical measures of NREM parasomnia and insomnia severities were similarly recorded
for a subgroup of eight patients at follow-up, demonstrating that patients continued to
improve post CBT-NREMP.
Conclusion: Our findings suggest that group CBT-NREMP intervention is a safe,
effective and promising treatment for NREM parasomnia, especially when precipitating
and perpetuating factors are behaviorally and psychologically driven. Future randomized
controlled trials are now required to robustly confirm these findings.
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INTRODUCTION
Non-Rapid Eye Movement (NREM) parasomnias, or arousal
disorders, are common in adults, where they represent a
constellation of different unwanted behaviors and experiences,
arising from or associated with sleep, for example from sleep
walking to sexsomnia (1). In addition to night-time symptoms,
they can also result in next day excessive tiredness, as well
as adversely affect mood, cognition, and quality of life (2).
Genetic predisposition plays a role and it is most evident
in sleepwalking (3). Arousal disorders can be an important
cause of sleep-related injury (4, 5), and it is crucial that their
severity can be reliably diagnosed and assessed. More recently,
Arnulf et al. (5) developed the Paris Arousal Disorders Severity
Scale (PADSS), which has been consistently demonstrated across
different NREM parasomnia phenotypes to reliably monitor and
measure the clinical symptoms and severity of arousal disorders.
The understanding of the exact neurobiology and the
maladaptive arousal mechanisms that underlie phenotypes
of NREM parasomnia remains in its infancy (3, 6–8).
Management is commonly multifaceted with an emphasis on
psychoeducation and ideally on non-pharmacological measures
(3). Pharmacotherapy is nonetheless frequently used in the
treatment of NREM parasomnias (9). However, it is not
always effective or wanted by patients, often because of fear
of side-effects and dependency (3). Treatment success rates
vary between different NREM parasomnia phenotypes, and
polypharmacy may be required (9). In some cases, certain
treatments, such as antidepressants, can worsen or even
precipitate parasomnia symptoms (10). As NREM parasomnias
are often chronic conditions, pharmacological treatment may
be required long-term, which is often undesirable, especially
when the patient is a young adult. Even when pharmacotherapy
is successful, NREM parasomnias can re-emerge following
treatment cessation, particularly if priming and precipitating
factors remain unaddressed (11).
Of note is that affective disorders, and especially anxiety
disorder, may lead to an increased frequency of negative
emotions in NREM parasomnia mentation, and that this in
turn may further increase daytime anxiety (12). Moreover, it
has been argued that the reported distress associated with
parasomnia/nightmare experience may have a more significant
impact on patients’ quality of life, even more so than the
frequency of parasomnic events [for an in-depth review of this
topic please refer to (12)]. In keeping with this, to date, several
psychotherapeutic approaches, for example: via Gestalt therapy
(13) and imagery rehearsal therapy (14), have been shown to
successfully target dysphoric parasomnias and to treat associated
significant clinical distress.
In order to address the growing need for non-pharmacological
therapies for NREM parasomnias (15), we have recently
developed a novel, group-based, Cognitive Behavioral Therapy
(CBT-NREMP) programme. The pathophysiological precipitants
of NREM parasomnias suggest that CBT interventions, which
address co-morbid insomnia, anxiety, stress and other relevant
psychological difficulties, may be beneficial in its management
(16). Our goal was therefore to primarily target factors whichmay
trigger and maintain parasomnias over time, by incorporating
and building-on core principles from the well-established and
cost-effective model (17) Cognitive Behavioral Therapy for
Insomnia (CBT-I) (18). The novel CBT for NREM parasomnia
(CBT-NREMP; Supplementary Material) protocol includes a
comprehensive programme that covers psychoeducation on the
etiology of NREMparasomnias, sleep hygiene, sleep rescheduling
to optimize homeostatic regulation, stimulus control to re-
establish an association between the bed/bedroom and sleep,
and specified body-based and cognitive relaxation techniques.
By changing maladaptive sleep-related behaviors, thoughts and
anxiety, CBT-NREMP treatment is specifically designed to target
those priming and precipitating factors which cause parasomnias
to persist over time. Moreover, it enables an individual to gain
insight into their own thoughts as well as their emotional and
behavioral processes regarding the self. The CBT programme is
delivered in a safe group environment that additionally utilizes
the spontaneity and creativity of the individual and the group.
Here we report on the preliminary treatment outcomes of our
novel CBT-NREMP programme.
MATERIALS AND METHODS
Design, Ethics, and Data Collection
All adult patients who had completed a whole programme
(i.e., five sessions) of structured group CBT-NREMP between
November 2018 and January 2020 were retrospectively identified,
and their clinical findings, including demographics and the
scores of several clinical questionnaires routinely used in our
tertiary sleep disorder center, were collected from the center’s
clinical sleep database and analyzed. Altogether 46 patients were
identified matching that criteria, and of those, a subgroup of
eight patients were identified for whom 3 to 6 months follow up
assessment findings were also available (Figure 1).
As per our clinical governance, framework the specified
requirements to enroll in CBT-NREMP included a previously
conducted video polysomnography (vPSG) investigation, and
a confirmed diagnosis of NREM parasomnia by a qualified
sleep physician, based on International Classification of Sleep
Disorders third edition (ICSD-3) criteria (1). In addition to
these inclusion criteria, all referred patients were screened
by an experienced psychiatrist/psychologist, to confirm and
assess their ability to participate in the group psychotherapy,
as well as to ascertain the patient’s ability to understand,
speak and write English language, and to confirm their
willingness and ability to give informed consent. The CBT-
NREMP exclusion criteria included: co-morbid sleep disorders
(apart from comorbid insomnia), current or past neurologic or
psychiatric illness, traumatic brain injury, current alcohol and/or
substance dependency disorders, developmental disorders and
intellectual disability.
For the purposes of this study, the effectiveness of CBT-
NREMP was evaluated by analyzing the outcomes of the three
major clinical questionnaires from the clinical sleep database,
including the Insomnia Severity Index (ISI) (19), Hospital
Anxiety and Depression Scale (HADS) (20), and the Paris
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FIGURE 1 | Flow diagram of the studied cohort. Nota Bene: some patients had n > 1 subtype of NREM parasomnia recorded. Percentages indicate the prevalence
of each NREM parasomnia subtype in our cohort. CBT-NREMP, cognitive behavioral therapy for non-REM parasomnia; CA, confusional arousal; SRED, sleep-related
eating disorder; NREM, non-REM; n, number.
Arousal Disorders Severity Scale (PADSS) (5) at baseline, post-
CBT-NREMP, and at follow-up (FU) 3 to 6 months later.
ISI is a self-rated scale, used to assess severity of insomnia in
the clinical and research settings (21). The scale uses a seven-item
self-report questionnaire that examines the nature, severity, and
impact of insomnia. The evaluated dimensions include severity
of sleep onset, sleep maintenance, and early morning awakening
problems, sleep dissatisfaction, interference of sleep difficulties
with daytime functioning, noticeability of sleep problems by
others, and distress caused by the sleep difficulties. A five-point
Likert scale is used to rate each item (e.g., 0 = no problem; 4
= very severe problem), yielding a total score ranging from 0 to
28 (21). Based on the total score the absence of insomnia (0–7);
sub-threshold insomnia (8–14); moderate insomnia (15–21); or
severe insomnia (22–28) can be identified (19). Similarly, HADS
is also a self-rated scale, used to assess severity of depression
and anxiety symptomatology (20). This 14-item scale includes
seven items each for anxiety and depression subscales, where
scoring for each item ranges from zero to three. A subscale score
>8 denotes anxiety or depression. PADSS is a self-administered
questionnaire designed to assess the severity of parasomnia
(5). The scale has excellent psychometric properties, as well
as valid and reliable subscales (22). It provides a means to
assess the efficacy of new intervention treatments, as well as
changes over longer periods of time. It consists of 17 items
related to severity of parasomnia, with total score ranges from
0 to 50 (5); the scale has three parts, including an inventory of
behaviors (PADSS-A), the frequency of episodes (PADSS-B), and
the general consequences of the disorder (PADSS-C). The scale
is self-completed and measured as follows: dangerous behaviors
(17 items with three possible answers: never = 0, sometimes =
1, often = 2), frequency of episodes (equal to or more than two
episodes per night= 6, one per night= 5, equal to or more than 1
episode per week= 4, equal to or more than 1 episode per month
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= 3, equal to or more than 1 episode per year= 2,<1 episode per
year = 1, never had any = 0), and consequences of the disorder
(5 items with three response options: never = 0, sometimes = 1,
often = 2). The best cutoff score for the overall PADSS (range
0–50) was found at 13/14 and had high sensitivity (83.6%) and
specificity (87.8%) (5). It has been shown in the past that the
complexity of behaviors emerging from N3 sleep as assessed by
the vPSG correlate positively with the scores for the PADSS-total,
PADSS-A, and PADSS-C (5, 22).
The study was granted ethical approval by the Hospital
Clinic Research Ethics Committee (Project-No-12025, GSTT
NHS, UK) to retrospectively ascertain anonymized data in full
compliance with the EU General Data Protection Regulation and
the Declaration of Helsinki.
CBT-NREMP Treatment
The structured group CBT programme consisted of five, weekly,
90min CBT-NREMP sessions, with a maximum of eight
participants per group. CBT-NREMP was conducted by an
experienced sleep medicine psychiatrist or a trained psychologist
according to a strict predetermined treatment protocol. Our
protocol provided therapists with clear guidance on how to
structure their therapy, as laid out in Supplementary Methods.
The first sessions focused on building a therapeutic alliance and
psychoeducation. The interventions sessions focused on both
short- and long-term goals. Different cognitive and behavioral
techniques (Supplementary Material) were applied to reach
these goals. Homework was given in each session with the
last session of therapy focusing on consolidation and relapse
prevention. Experienced CBT-clinicians monitored adherence
to the treatment principles in weekly group supervisions
throughout the therapy period to ensure treatment fidelity.
Clinical notes from the therapy sessions were regularly reviewed
during supervisory sessions with focus on the initial phase of
treatment, case formulation, treatment strategy and termination
of therapy.
Statistical Analyses
Descriptive statistics were used to summarize the data as mean
± standard deviation (SD), and with median, 25th and 75th
percentiles for continuous non-parametric variables. Due to
non-normality of the data, as assessed by Kolmogorov-Smirnov
test, the non-parametric Wilcoxon signed rank test (paired
comparisons) withHolm-Bonferroni corrections was used (5, 23)
to test difference in severity between the CBT-NREMP group’s
insomnia (i.e., ISI), parasomnia (i.e., PADSS) and depressive and
anxiety symptomatology (i.e., HADS) pre- and post-CBT scores.
In addition, post hoc analyses were done for differences across
the three time points, at the baseline, immediately following
the CBT-NREMP and at the 3 to 6 months follow up (i.e.,
pre-, post-, and FU) for eight participants for whom follow-up
data were available. A value of P < 0.05 was considered to be
statistically significant and Holm-Bonferroni corrections were
performed for the post-hoc analyses. The analyses were done
using a statistical package R, version 4.0.2 for all statistical
analyses (24).
RESULTS
Forty-six patients, of whom 25 were male (54.3%), aged 19
to 73 years-old (mean ± SD: 35.8 ± 11.4 years) underwent
a structured, comprehensive 5 weeks CBT-NREMP group
intervention. Patients were asked to complete baseline ISI,
HADS, and PADSS assessments prior to starting CBT-NREMP,
and the same assessments were subsequently completed after the
CBT-NREMP intervention (Tables 1, 2).
At the baseline, patients’ PADSS scores reflected the clinical
severity of their untreated NREM parasomnia (mean PADSS
score: 19.46 ± 6.32; Table 1). Patients scored moderately high
on clinical measures of insomnia (ISI: 15.28 ± 4.36), with the
baseline HADS outcome scores suggestive of subthreshold levels
of anxiety and low mood (HADS-A: 8.14 ± 4.84 vs. HADS-D:
7.02± 4.05).
The CBT-NREMP intervention successfully reducedmeasures
of clinical severity of NREM parasomnia (PADSS: PPrevsPost
= 0.00032; Table 2). Further significant improvements
were noted in clinical measures of insomnia (ISIPrevsPost:
P = 0.000054; Table 2), which were reduced to clinical
subthreshold values (Table 1), as well as in patients’ self-reported
severity of anxiety and depressive symptoms (HADSPrevsPost:
P = 0.037; Table 2).
Preliminary Findings on Sustainability of
the CBT-NREMP Intervention
A subgroup of eight patients (17.4%) was followed after the
CBT-NREMP intervention for up to 6 months (please also
see Supplementary Material). By comparison to the socio-
demographics of the larger group, the smaller subgroup consisted
of younger (29.5 ± 8.1 years), predominantly female (six, 75%)
patients, who at the outset reported higher clinical measures
of severity of NREM parasomnia (PADSS scores: 24.75 ± 3.62;
Supplementary Table 1) and anxiety (HADS-A: 11.25 ± 5.18;
Supplementary Table 1).
Here, the CBT-NREMP intervention also significantly
reduced the clinical measures of severity of NREM
parasomnia and insomnia (Supplementary Table 2). These
improvements were maintained, with further reduction
in clinical measures of frequency and severity for NREM
parasomnia and insomnia reported to continue for up to 6
months following the intervention (ISI: P = 0.042; PADSS: P =
0.041; Supplementary Table 2).
The CBT-NREMP intervention, however, did not lead to
a statistically significant reduction in clinical measures of low
mood and anxiety for this subgroup (HADS: P = 0.22).
Nonetheless, the longitudinal reduction in the mean HADS
scores was recorded across the assessment time-points (HADS
Pre: 17.5 ± 8.64; Post CBT-NREMP: 14.88 ± 4.52; FU 3 to 6
months:11.88 ± 7.02; Supplementary Table 1), with the most
consistent improvement reported to occur during the follow-up
period of up to 6 months after the intervention (HADS-A: P
= 0.057; Supplementary Table 2). This may suggest a delayed
nature of this response, or its secondary development as a
consequence of primary improvements in sleep measures.
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TABLE 1 | Outcomes of ISI, HADS, and PADSS assessments in 46 NREM parasomnia patients at baseline (Pre) and following the CBT-NREMP treatment (Post).
Assessment Pre Post
Mean (SD) Median (Q1, Q3) Mean (SD) Median (Q1, Q3)
ISI 15.28 (4.36) 15 (12.25, 18) 12.09 (4.6) 12 (9.25, 15)
HADS 15.18 (6.55) 16 (11,19) 13.13 (5.98) 13 (8, 17.75)
HADS-A 8.14 (4.84) 7 (4.75, 12) 7.22 (4.24) 7 (4, 9.75)
HADS-D 7.02 (4.05) 6 (4,10) 5.91 (3.74) 6 (3,9)
PADSS 19.46 (6.32) 19 (16, 23.75) 17.53 (6.11) 17 (14,22)
PADSS-A 9.8 (4.67) 10 (6.25, 13.5) 8.41 (4.16) 8 (5,10)
PADSS-B 4.41 (1.11) 4 (4,5) 4.46 (1.21) 4 (4, 5.75)
PADSS-C 5.24 (1.78) 5 (4,7) 4.84 (2.01) 5 (3, 6.25)
ISI, Insomnia Severity Index; HADS, Hospital Anxiety and Depression Scale (total score); HADS-A, Hospital Anxiety and Depression Scale-Anxiety subset score; HAD-D, Hospital Anxiety
and Depression Scale—Depression subset score; PADSS, Paris Arousal Disorders Severity Scale (total score); PADSS-A, Paris Arousal Disorders Scale-subset A score; PADSS-B,
Paris Arousal Disorders Scale subset-B score; PADSS-C, Paris Arousal Disorders Scale subset-C score. Q1, 25% percentile. Q3, 75% percentile. SD, standard deviation.
TABLE 2 | Results of Wilcoxon signed rank tests comparing pre- and post-CBT-NREMP intervention scores for ISI, HADS, and PADSS assessments in 46 NREM
parasomnia patients.
Assessment Difference from Pre- to Post-CBT median (Q1, Q3) Difference in median (95% CI) Wilcoxon signed rank test P-value
ISI 3 (0, 6.75) 3 (1, 6) 710.5 0.000054
HADS 1 (−1, 6) 3 (−0.84, 5.84) 514.5 0.037
HADS—A 1 (−1, 3) 0 (−1, 2.97) 512 0.089
HADS—D 1 (0, 2) 0 (−2, 3.5) 467.5 0.034
PADSS 1 (0, 3) 2 (−1.40, 6) 560 0.00032
PADSS—A 1 (−0.75, 2.75) 2 (0, 3.5) 600.5 0.003
PADSS—B 0 (0, 0) 0 (−1, 1) 71.5 0.826
PADSS—C 0 (−0.25, 1) 0 (−1, 2) 306.5 0.119
ISI, Insomnia Severity Index; HADS, Hospital Anxiety and Depression Scale; PADSS, Paris Arousal Disorders Severity Scale. Q1, 25% percentile. Q3, 75% percentile. CI, confidence
interval. CBT, cognitive behavioral therapy. Statistically significant values are shown in bold.
DISCUSSION
The findings of our longitudinal study support the clinical utility
for a novel CBT-NREMP intervention that targets distinct sleep,
behavioral and emotional regulation factors. More specifically,
we demonstrate that 5 weeks of a structured group CBT
intervention in adult patients with NREM parasomnia can lead
to a significant reduction in its severity. This is shown by a robust
reduction in total PADSS and PADSS-A patients’ scores (Table 1),
both known to closely correlate with vPSG-ascertained severity
(and complexity) of parasomnia behaviors that emerge from N3
sleep (5, 22).
In addition, we demonstrate that CBT-NREMP intervention
can simultaneously lead to a clinically significant reduction in
the patients’ severity of insomnia, as evidenced by the reduction
in the ISI scores. In our study, the ISI scores were robustly
reduced frommoderate to subthreshold values, with concomitant
improvement in affective symptomatology (Table 1).
We also demonstrate that the effects of CBT-NREMP
can be maintained, and that they continue to improve over
a period of up to 6 months following the intervention
(Supplementary Table 2). To the best of our knowledge, our
study is the first to demonstrate the effectiveness, and arguably
also the safety, of a structured CBT for adult NREM parasomnia.
Utilizing CBT in the treatment of sleep disorders holds
substantial promise, and is clinically expanding (25). Where once
medication-only treatments were favored, there has recently been
a paradigm shift toward CBT-based interventions, which are
viewed more favorably by patients (26), and treatment guidelines
(27). CBT for insomnia (CBT-I) is already well-established
as the gold-standard treatment, and principally operates by
reducing perpetuating and precipitating factors associated with
the condition (28). NREM parasomnias similarly manifest with
priming (e.g., sleep loss, anxiety, stress, poor sleep hygiene), and
precipitating factors (e.g., environmental noise) (16). Therefore,
they should be amenable to a targeted CBT intervention, as our
study amply demonstrates. Treating NREM parasomnias with
CBT-NREMP, as opposed to medication, may have a number
of potential advantages, including fewer known side-effects, and
an explicit focus on treating the factors that may be responsible
for perpetuating parasomnias in an effort to produce more
durable effects.
Despite this, the body of literature on cognitive and behavioral
interventions for NREM parasomnia is limited to case reports
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or smaller case-series, which often target just one parasomnia
phenotype (29). In the past, selective application of CBT-I,
mindfulness-based stress reduction and CBT for stress have been
shown to helpfully target all phenotypes of NREM parasomnias
(9). In our experience, patients with NREM parasomnia
commonly struggle to benefit from other CBT paradigms,
where they often feel apart from the rest of the group. For
example, it can be understandably challenging for a patient with
sleepwalking to engage in, and accept, a therapy which solely
focuses on insomnia. Indeed, the development of our targeted
group CBT-NREMP arose in part from this unmet patient need.
Despite the striking and sustainable improvements reported
by our patients, several notable limitations merit further
mention. Firstly, CBT-NREMP was designed as an economical
and inclusive group intervention, which could be potentially
delivered in a variety of clinical settings and that reliably targets
diverse physiologic phenotypes of arousal disorders. Whilst
this was beyond the scope of our study, future studies should
ideally examine whether taking a stepped-care approach would
be more beneficial for different settings or NREM parasomnia
phenotypes, possibly avoiding any potential selection bias.
For example, any such multifaceted CBT-NREMP intervention
could arguably start with group therapy sessions that address
common therapeutic targets in parasomnia (e.g., safety, sleep
hygiene), with subsequent individual interventions focusing on
specific and more complex phenotypes, such as trauma-related
presentations and sexomnia.
Secondly, whilst the findings of our study suggest that a
robust short term (e.g., 3 to 6 months) maintenance of CBT-
NREMP effects is possible, this effect was only shown in eight,
as opposed for 46 original study patients, due to unforeseen
and early study closure during the Covid-19 pandemic. This
smaller subgroup had a widely differing sociodemographic in
that the patients were notably younger, they reported higher
baseline anxiety, and they were predominantly women. Hence,
the CBT-NREMP sustainability should be confirmed in a
larger patient cohort, and the specific CBT-NREMP effects and
their sustainability ideally recorded over a significantly longer
period of time.
Another potential limitation worth mentioning is that our
assessment was based primarily on patients’ subjective reports.
The self-reported scores, recorded in PADSS, ISI and HADS
questionnaires are, however, widely used, and all three have
been robustly validated for clinical and research purposes (5,
21, 30). Nonetheless, the subjective nature of patients’ reports
may arguably render any truly objective interpretation of
CBT-NREMP’s effectiveness invalid. We challenge the clinical
significance of this limitation, given that the major aim of any
clinical treatment of NREM parasomnia is primarily offered to
ensure patients’ safety, and secondly, to address the patients’
symptoms according to their own criteria (9).
Taken together, the findings of our study demonstrate that
structured group CBT for adult NREM parasomnia is a safe,
effective, and a highly promising treatment. Due to its unique
design, CBT-NREMP intervention may be especially effective in
those patients in whom precipitating and perpetuating factors are
likely behaviorally and psychologically driven. However, in order
to reliably build on our preliminary study, future randomized
controlled trials are required. Ideally, any such trial should
include prospective multimodal physiologic and neuroimaging
investigation to decipher neuromechanisms which underlie
and promote differential effects of CBT-NREMP’s intervention.
Following this approach, it is hoped that with time we will
also gain further insight into the role that patients’ gender and
their emotional fragility may play. Going forward, it would
be important to understand how they may impact objective
CBT-NREMP outcomes, including the electroencephalographic
arousal signatures and their behavioral correlates.
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